Abstract
The superiority of intra-arterial infusion with methotrexate (MTX) over its systemic use in the treatment of head and neck tumours is still being questioned. A model in the rat, suitable for intra-arterial administration of MTX could be constructed. In this model 3 schedules have been investigated: (1) 7 days continuous intra-arterial infusion with MTX; (2) the same schedule combined with leucovorin (CF) 6-hourly intraperitoneally (i.p.) after Sullivan et al. (1959); (3) intermittent administration of MTX 2 × 24 h intra-arterial infusion on Day 1 and 4, while on Day 2, 3, 5, 6 and 7 the catheter is kept open by the continuous intra-arterial infusion of saline. For all the three schedules intra-arterial MTX proved to be superior to its systemic use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Sindram, P., Snow, G. & van Putten, L. Intra-Arterial Infusion with Methotrexate in the Rat. Br J Cancer 30, 349–354 (1974). https://doi.org/10.1038/bjc.1974.204
Issue Date:
DOI: https://doi.org/10.1038/bjc.1974.204
This article is cited by
-
Pharmacokinetics of intra-arterial tumour therapy
Archives of Oto-Rhino-Laryngology (1984)
-
Tierexperimentelle Untersuchungen zur intraarteriellen Chemotherapie mit Bleomycin
Archives of Oto-Rhino-Laryngology (1980)